6-K 1 tm2315170d1_6k.htm FORM 6-K

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2023

 

Commission File Number: 001-41359

 

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

 

Not Applicable

(Translation of Registrant´s name into English)

 

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x        Form 40-F ¨

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨        No x

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨        No x

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form 6-K is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934 Yes ¨ No x

 

 

 

 

 

 

On May 10, 2023, Belite Bio, Inc issued a press release entitled “ Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on F-3 (No. 333-271549) and Form S-8 (No. 333-266060) of Belite Bio, Inc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit 99.1 — Press Release

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Belite Bio, Inc
   
  By: /s/ Yu-Hsin Lin
  Name: Yu-Hsin Lin
  Title: Chief Executive Officer and Chairman

 

Date: May 10, 2023